Table 3 Clinical features and procedural characteristics by antithrombotic treatment group
Nothing n = 93 | UFH n = 153 | UFH + Abcx n = 44 | Abcx n = 65 | Bivalirudin n = 24 | Enoxaparin n = 18 | p | |
|---|---|---|---|---|---|---|---|
Age (years) | 61 ± 13 | 60.3 ± 14 | 61.3 ± 11 | 55.4 ± 4 | 61 ± 11 | 63.9 ± 9 | <0.001 |
Females | 15 (16) | 21 (13.7) | 6 (13.6) | 7 (10.7) | 1 (4.2) | 4 (22) | 0.2 |
Weight (kg) | 77.5 ± 10 | 81 ± 13 | 81 ± 12 | 80 ± 13 | 81 ± 12 | 81 ± 17 | 0.01 |
Hypertension | 51 (54.8) | 74 (48.3) | 18 (40.9) | 30 (46) | 14 (58.3) | 9 (50) | 0.2 |
Smoking | 50 (53.7) | 81 (53) | 24 (54.5) | 43 (66) | 17 (70.8) | 9 (50) | 0.1 |
Diabetes | 23 (24.7) | 34 (22.2) | 3 (6.8) | 13 (20) | 4 (16.6) | 5 (27.7) | 0.04 |
Dyslipidemia | 47 (50.5) | 69 (45) | 15 (34) | 31 (47.6) | 15 (62.5) | 8 (44) | 0.03 |
Previous stroke | 3 (3.2) | 8 (5.2) | 1 (2.2) | 2 (3) | 0 | 1 (5.5) | 0.5 |
Previous infarction | 7 (7.5) | 14 (9.1) | 1 (2.2) | 11 (16.9) | 4 (16.6) | 3 (16.6) | 0.03 |
Peripheral vascular disease | 5 (5.4) | 6 (3.9) | 2 (4.5) | 1 (1.5) | 1 (4.2) | 1 (5.5) | 0.05 |
Coronary surgery | 1 (1) | 2 (1.3) | 0 | 1 (1.5) | 0 | 0 | 0.4 |
SBP at admission (mmHg) | 135 ± 28 | 123 ± 27 | 117 ± 22 | 127 ± 24 | 113 ± 30 | 120 ± 24 | <0.001 |
HR at admission (bpm) | 78 ± 19 | 77.5 ± 19 | 75.7 ± 19 | 79 ± 20 | 74 ± 19 | 67 ± 15 | 0.02 |
Creatinine (mg/dL) | 1.1 ± 0.6 | 0.9 ± 0.3 | 1 ± 1 | 1 ± 0.3 | 0.9 ± 0.2 | 1 ± 0.2 | <0.001 |
Baseline hematocrit (%) | 40 ± 10 | 41.5 ± 5 | 41 ± 6 | 37 ± 12 | 40.8 ± 7 | 38.3 ± 11 | <0.001 |
Anterior infarction | 50 (53.7) | 62 (40.5) | 22 (50) | 31 (47.6) | 11 (45.8) | 9 (50) | 0.05 |
Ejection fraction (%) | 46.6 ± 11 | 50.8 ± 12 | 51 ± 14 | 47 ± 13 | 50 ± 13 | 50.7 ± 11 | 0.02 |
Pain onset to thrombolysis | 120 | 121 | 105 | 105 | 120 | 88 | 0.09 |
Thrombolysis to rescue | 167 | 164 | 205 | 168 | 182 | 175 | 0.003 |
TNK-tPA + enoxaparin | 89 (95.6) | 144 (94) | 39 (88.6) | 60 (92.3) | 21 (87.5) | 17 (94.4) | 0.2 |
Killip class III-IV | 12 (13) | 12 (7.8) | 5 (11.4) | 11 (17) | 5 (20.8) | 0 | 0.08 |
Radial access | 19 (20.4) | 100 (65.3) | 31 (70.4) | 11 (17) | 11 (45.8) | 17 (94.4) | <0.001 |
Baseline TIMI | 1.7 ± 1.3 | 1.4 ± 1.3 | 0.57 ± 1 | 0.78 ± 1 | 0.75 ± 1.2 | 16 ± 1.3 | <0.001 |
Final TIMI | 2.8 ± 0.7 | 2.9 ± 0.5 | 2.75 ± 0.7 | 2.7 ± 0.6 | 2.8 ± 0.6 | 3 ± 0 | 0.01 |
Baseline TIMI 0–1 | 38 (40.8) | 77 (50.3) | 36 (81.8) | 45 (69.2) | 18 (75) | 6 (33.3) | <0.001 |
Final TIMI 3 | 86 (92.5) | 143 (93.4) | 35 (79.5) | 51 (78.4) | 22 (91.6) | 18 (100) | 0.003 |
Thrombus aspiration | 23 (24.7) | 56 (36.6) | 28 (63.6) | 38 (58.4) | 13 (54.2) | 6 (33.3) | 0.001 |
Number of stents | 1.2 ± 0.6 | 1.3 ± 0.7 | 1.37 ± 0.9 | 1.27 ± 0.8 | 1.08 ± 0.6 | 1.1 ± 0.5 | 0.1 |
Multivessel disease | 41 (44) | 48 (31.4) | 18 (40.9) | 27 (41.5) | 13 (54.2) | 8 (44) | 0.04 |
2nd PCI | 7 (7.5) | 18 (11.7) | 7 (16) | 6 (9.2) | 5 (20.8) | 0 | 0.1 |
Clopidogrel load 300 mg | 85 (91.4) | 126 (82.3) | 37 (84) | 55 (84.6) | 19 (79.2) | 11 (61) | 0.002 |